ENEDYM
Enedym Inc. ( “Enedym”), the technology company that develops next generation switched reluctance motors (SRMs), electric propulsion, and electrified powertrains, announced today that it formed a partnership with the Napino Group. (“Napino”), one of India's leading suppliers of automotive electronic products. Under the terms of the partnership, Napino will license Enedym’s switched reluctance motor (SRM) technology for use in 2-wheel electric motorcycles and scooters in India.
Dr. Ali Emadi, Founder, President, and CEO of Enedym commented, “We are excited to announce this deal with Napino. The partnership between Enedym and Napino is transformative and significant given it will provide a more stable and secure global manufacturing supply chain, combined with sustainable next generation motor technology. The landscape of the automotive industry is changing rapidly and we are excited to provide next generation electric motor technology that aligns with the needs of leading OEMs. Through the use of Enedym’s SRMs – which eliminate the need for rare earth metals often sourced exclusively from China – we are providing a gateway to low cost/high quality manufacturing of next generation motors, inverters, and controllers.
Dr. Emadi added, “We are in the midst of a historic shift, both in terms of electrification, focus on sustainability, and the need for secure and stable supply chains. Partnering with Napino will allow us to supply our next generation motor technology within a massive market and offer Indian based and global OEM’s a viable manufacturing alternative to China.”
Mr. Vaibhav Raheja, Joint Managing Director of Napino commented, “We are extremely delighted to announce our partnership with Enedym. Achieving removal of magnets and rare earth elements in these products offers great advantages not only from a geo-political point of view, but also ensures sensible use of natural resources. We are confident that the affordable and robust solution being created by our engineering & manufacturing teams will offer quicker adoption of electric mobility in India. Our vision is to make India a global manufacturing hub for EV motors and contribute towards making it carbon neutral.”
Commenting on the partnership, Mr. Naveen Kumar, Group CEO of Napino, said; “Zero emission mobility has become a global movement & with Enedym as our partner, we are gearing up to meet the current & future requirements of electric mobility. As a technology driven organization, Napino has constantly reinforced its position as a leading Auto Electronics System Supplier, offering innovative, sustainable and robust solutions for its customers. Working on cutting-edge technologies ensures that we continue to be at the forefront of the rapidly transforming business landscape.”
Sumit Dhanuka, Founder & Managing Partner of Precog Innovation Partners, commented, "We are excited to have enabled this unique strategic partnership between Napino and Enedym. This collaboration brings together Enedym’s cutting-edge design and development capabilities in the SRM motor technology space and Napino’s strong automotive manufacturing and go-to-market strengths in the Indian market, helping us realize the shared vision towards Net-Zero Mobility and an Aatmanirbhar Bharat (Self-reliant India).”
Enedym recently announced a $15 million financing round from an international group of strategic investors within the U.S., Canada, Europe, and India.
About Enedym, Inc.
Enedym is a technology start-up company from McMaster University. The company is headquartered at the McMaster Innovation Park in Hamilton, Ontario, Canada. Enedym has ownership of over 50 patents and pending patent applications and related inventions developed by the Canada Excellence Research Chair in Hybrid Powertrain Dr. Ali Emadi and his research group at the McMaster Automotive Resource Centre (MARC), McMaster University. Enedym’s vision is to reduce the cost of electric propulsion motors significantly and power a new paradigm in the electric motor industry through novel switched reluctance motor (SRM) drive technologies. Enedym aspires to help save the planet, one electric motor market at a time. To learn more about Enedym, please visit www.enedym.com and our YouTube channel at Enedym YouTube .
Napino Auto & Electronics Ltd
Napino is one of India's leading supplier of automotive electronic products. It employs roughly 6000 employees. The portfolio includes ECUs, capacitor-discharge ignitor, regulator rectifier, wiring harness, handlebar switches, and E Mobility products among other electronic offerings. As a leader in its segment with complete design, development, and manufacturing capabilities, Napino offers innovative solutions to major automobile manufacturers. Through its robust R&D capabilities and sustainable partnerships with global players, Napino aspires to lead technology innovation in automotive electronics. To learn more, please visit http://napino.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005029/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom